Cash conversion trending down
Cash conversion (CFO ÷ profit) has averaged 1.58× over the last 3 profit-making years versus 2.11× before that.
Importance 64 / 95 · cash quality
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Cash conversion (CFO ÷ profit) has averaged 1.58× over the last 3 profit-making years versus 2.11× before that.
Importance 64 / 95 · cash quality
Revenue grew 21.4% but profit grew 11.9%, so the company kept less of each rupee of revenue as profit.
Importance 64 / 95 · growth
Revenue compounded at 13.2% a year over 4 years (₹8,508 → ₹13,980).
Importance 54 / 95 · growth
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue grew 13.2% a year over 4 years, from ₹8,508 cr in FY2022 to ₹13,980 cr in FY2026. Net profit grew 28.8% a year over the same period.
Revenue grew 21.4% but profit grew 11.9%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Revenue compounded at 13.2% a year over 4 years (₹8,508 → ₹13,980).
Over 4 years profit compounded at 28.8% a year while revenue compounded at 13.2% a year — though FY2023 saw a one-off step-change of 60% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Revenue grew 21.4% year on year (FY2025 → FY2026).
In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,979 cr (up 50.8% on the same quarter last year) and net profit ₹534 cr (down 9.6%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 revenue was ₹4,979 cr, up 50.8% from ₹3,302 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 EBIT was ₹1,047 cr, up 22.9% from ₹852 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
Q2 FY27 interest (finance cost) was ₹300 cr, up 525.0% from ₹48 cr a year earlier.
Rule QTR_INTEREST_EXPENSE_CHANGE_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 2,809 | +2.8% | 503 | +13.5% | 17.9% |
| Q4 FY25 | 2,959 | +7.8% | 498 | +10.9% | 16.8% |
| Q1 FY26 | 3,178 | +11.2% | 548 | +19.9% | 17.2% |
| Q2 FY26 | 3,302 | — | 591 | — | 17.9% |
| Q3 FY26 | 3,303 | +17.6% | 635 | +26.2% | 19.2% |
| Q4 FY26 | 4,197 | +41.8% | 364 | −26.9% | 8.7% |
| Q1 FY27 | 4,921 | +54.8% | 566 | +3.3% | 11.5% |
| Q2 FY27 | 4,979 | +50.8% | 534 | −9.6% | 10.7% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 31.9% in FY2026, against 30.9% in FY2022. ROE was 17.0% and ROCE 15.6% in FY2026.
ROE declined from 26.5% to 17.0% year on year.
Rule ROE_DETERIORATED_YOY
Debt-to-equity was 0.84x in FY2026, against 0.67x in FY2022; interest coverage 8.69x. Operating cash flow was 1.41x net profit.
Cash conversion (CFO ÷ profit) has averaged 1.58× over the last 3 profit-making years versus 2.11× before that.
Rule CASH_CONVERSION_DETERIORATING
Net worth compounded at 31.1% a year over 4 years (₹5,953 → ₹17,585) — though FY2026 saw a one-off step-change of 132% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.41×).
Debt-to-equity rose from 0.40× to 0.84× year on year.
Free cash flow has been positive in 5 of the last 5 years.
Within its 12-company Pharmaceuticals peer group, it ranks 4 of 12 on return on equity and 5 of 12 on EBITDA margin. Its P/E of 75.8 compares with a peer median of 45.3.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
TORNTPHARM · 4th of 12 · set median 14.8%
TORNTPHARM · 5th of 12 · set median 28.7%
TORNTPHARM · 4th of 12 · set median 14.4%
TORNTPHARM · 9th of 12 · set median 45.3×
Trades at 75.77× earnings — 67% above the pharmaceuticals median of 45.29×.
Rule PE_ABOVE_PEERS
On the trailing twelve months. Last full year: P/E 74.4× · P/S 11.4× · ROE 17.0%. TTM and full-year revenue and EBITDA differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
The share price is up 26.3% over 1 year, up 122% over 3 years (30.4% a year) and up 237% over 5 years (27.5% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 8.3% below its 52-week high.
Over 4 years profit (28.8% a year) and the stock (30.4% a year) compounded at roughly the same rate — but FY2022 profit (₹777) was well below the through-cycle level (~₹1,656), so this rate is inflated by the recovery from a low base.
Rule STOCK_TRACKED_EARNINGS · recovery
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 |
| Total income | 8,705 | 9,665 | 10,786 | 11,539 | 13,886 |
| EBITDA | 2,628 | 2,887 | 3,426 | 3,744 | 4,465 |
| Profit before tax | 1,226 | 1,847 | 2,352 | 2,673 | 2,872 |
| Net profit | 777 | 1,245 | 1,656 | 1,911 | 2,138 |
| EPS (₹) | 45.9 | 36.8 | 48.9 | 56.5 | 63.9 |
| Net worth | 5,953 | 6,198 | 6,856 | 7,591 | 17,585 |
| Total debt | 4,018 | 5,297 | 3,938 | 3,026 | 14,798 |
| Operating cash flow | 1,803 | 2,368 | 3,266 | 2,585 | 3,023 |
| Free cash flow | 1,606 | 1,953 | 2,967 | 1,992 | 2,387 |
| Ratio | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth YoY | — | 13.1 | 11.5 | 7.3 | 21.4 |
| Profit growth YoY | — | 60.2 | 33.0 | 15.4 | 11.9 |
| Profitability | |||||
| EBITDA margin % | 30.9 | 30.0 | 31.9 | 32.5 | 31.9 |
| Net margin % | 8.9 | 12.9 | 15.4 | 16.6 | 15.4 |
| Return on equity % | 13.1 | 20.5 | 25.4 | 26.5 | 17.0 |
| Return on capital % | 19.7 | 20.3 | 23.5 | 27.5 | 15.6 |
| Leverage & cash | |||||
| Debt to equity | 0.67 | 0.85 | 0.57 | 0.40 | 0.84 |
| Cash flow ÷ profit | 2.32 | 1.90 | 1.97 | 1.35 | 1.41 |
| Current ratio | 1.17 | 0.98 | 1.03 | 1.19 | 1.13 |